CHAPEL HILL, N.C., July 27, 2012 /PRNewswire/ -- Pharmaceutical and biotech companies are constantly faced with the challenge of delivering innovative new products at lower development costs. Activities such as ad boards, KOL identification & management, clinical trial strategy & planning, and publication strategy & planning, are central to the new product planning process.
They also represent the activities where organizations turn to Medical Affairs to play a lead role. To give Medical Affairs leaders insights into the timing and value of these activities, Best Practices, LLC conducted research that produced the report "New Product Planning: Role and Activities for Medical Affairs ."
In addition to benchmarks that illustrate when organizations conduct Medical Affairs activities in the development cycle, the report provides narratives from new product planning veterans on how organizations approach these critical activities.
This 50-slide report provides drill down for each of these activities in terms of their timing, intended outcomes, and value for the organization:
- Advisory Boards
- Branding of the Science
- KOL Identification
- KOL Management
- Medical Meeting Planning
- Non-Registration Trials Strategy and Planning
- Publication Strategy & Planning
To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr1164.htm. 
Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, co